CYAD - CYAD STOCK NEWS

Celyad Oncology announced the commencement of the KEYNOTE-B79 Phase 1b trial, evaluating CYAD-101 in combination with KEYTRUDA® for treating refractory metastatic colorectal cancer (mCRC) with microsatellite stable (MSS) disease. The first patient has been dosed, marking a significant step in assessing CYAD-101's potential. Preliminary data presented at the ASCO Gastrointestinal Cancers Symposium indicate promising results. The collaboration with MSD aims to explore the efficacy of this combination therapy, with initial results expected next year.

Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced receipt of a transparency notification as of December 10, 2021, indicating that CFIP CLYD LLC, an affiliate of Fortress Investment Group, has crossed the 25% ownership threshold. This entity now holds 6,500,000 shares, representing 28.77% of Celyad's shares and 26.04% of voting rights as of December 8, 2021. The notification is a legal requirement following the acquisition of voting securities, affirming Fortress's significant stake in the company.

Celyad Oncology SA (CYAD) announced a transparency notification revealing that CFIP CLYD LLC, an affiliate of Fortress Investment Group, has acquired 28.77% of its shares, equating to 6,500,000 shares, as of December 8, 2021. This acquisition crossed the statutory threshold of 25%. Fortress Investment Group LLC indirectly controls CFIP CLYD LLC and has no controlling shareholder. The notification reflects substantial voting rights, now at 26.04%. This shift may impact shareholder dynamics and the overall governance of Celyad Oncology.

Celyad Oncology announced updates from its CYAD-02 and CYAD-211 clinical programs, showcasing the efficacy of its non-gene edited shRNA technology at the 63rd ASH Annual Meeting. The Phase 1 CYCLE-1 trial of CYAD-02 for r/r acute myeloid leukemia reported a favorable tolerability profile and promising initial clinical activity. In the Phase 1 IMMUNICY-1 trial of CYAD-211 for r/r multiple myeloma, early data showed good tolerability and some patients achieving partial responses. Upcoming enhancements in treatment regimens are planned to maximize clinical benefits.

Celyad Oncology SA has completed a private placement, issuing 6.5 million shares at USD 5.00 each, raising USD 32.5 million. The funds will support research and development, including clinical work on CAR T therapies CYAD-101 and CYAD-211, and advance other preclinical candidates. The shares sold are unregistered under U.S. securities laws and come with customary resale registration rights. Celyad focuses on CAR T therapies for cancer, with a growing pipeline of products.

Celyad Oncology has announced a private placement of 6,500,000 ordinary shares with Fortress Investment Group, generating gross proceeds of USD 32.5 million (approximately EUR 28.7 million). The shares will be priced at USD 5.00 each, reflecting an 18.5% premium to the 30-day volume weighted average price. Proceeds will support R&D, including CAR T candidates CYAD-101 and CYAD-211. Following the placement, Fortress will hold 28.8% of Celyad's shares. This financing is expected to fund activities into the first half of 2023.

Celyad Oncology SA (CYAD) has announced a subscription agreement with Fortress Investment Group for the private placement of 6.5 million ordinary shares, generating gross proceeds of USD 32.5 million. The shares will be offered at USD 5.00 each, an 18.5% premium over the 30-day volume weighted average price. The funds will support research and development, including clinical trials for CAR T candidates CYAD-101 and CYAD-211. Fortress will acquire 28.8% of Celyad's shares and gain certain rights, including board nominations and rights on new equity issuance.

Celyad Oncology (Euronext & Nasdaq: CYAD) presented preclinical data at the SITC Annual Meeting, highlighting advancements in their allogeneic CAR T therapy programs. Key findings include the improvement of NKG2D CAR T cells' anti-tumor activity through IL-18 armoring, and the development of a second-generation shRNA scaffold for enhanced CAR T candidates. Notably, the KEYNOTE-B79 Phase 1b trial, evaluating CYAD-101 in combination with KEYTRUDA, is set to initiate in Q4 2021, targeting patients with microsatellite stable metastatic colorectal cancer, addressing a significant unmet medical need.

Celyad Oncology (CYAD) announced key developments in its clinical trials and financials for Q3 2021. The Phase 1b KEYNOTE-B79 trial is set to evaluate CYAD-101 with KEYTRUDA in mCRC patients by year-end 2021. Enrollment in the IMMUNICY-1 trial for CYAD-211 continues, with updates to be presented at the upcoming ASH Annual Meeting. The company secured a €3.5 million grant and signed a patent agreement for targeting GPC3. As of September 30, 2021, Celyad had €6.1 million in cash, down from €12 million in Q2.